Seaside Storage Opens on Hwy 101 with 65 Heated Units, Online Booking

Seaside Storage Opens on Hwy 101 with 65 Heated Units, Online Booking
Locally owned facility serves Seaside, Gearhart, Cannon Beach, and the north Oregon coast

SEASIDE, Ore. – Seaside Storage, a new locally owned self-storage facility on Highway 101, is officially open for business. The facility held its ribbon cutting with the Seaside Chamber of Commerce last month and is now taking reservations from residents, vacation home owners, and businesses across the north Oregon coast.

Located at 1685 N Roosevelt Drive, Seaside Storage offers 65 heated units in three sizes: 5×10 walk-up units at $99 per month, 5×10 drive-up units at $119 per month, and 10×20 drive-up units at $249 per month. New tenants receive their first month free on 5×10 units with deposit.

The facility features electronic gated access with personal codes for each tenant, 24-hour camera monitoring, perimeter fencing, and a well-lit lot. Access hours are 6:00 a.m. to 9:00 p.m., seven days a week. The entire rental process is conducted online — tenants can browse available units, sign a lease, pay the first month, and receive their gate code within about five minutes at SeasideStorage.com.

“Seaside is growing, and the community needed a modern, high-security storage option that’s centrally located and built to protect what people put in it,” said Seth Morrisey, owner of Seaside Storage. “We built this for our neighbors — heated, secure, easy to use, and locally owned.”

Morrisey is a lifelong Seaside resident, the owner of a local marketing agency, and currently serves as President of the Seaside City Council.

A second phase is planned for summer 2027, adding 90 climate-controlled units and bringing the facility’s total capacity to 155 units. The expansion will introduce climate-controlled storage to the Seaside market, offering humidity-regulated protection for items including fine furniture, electronics, photographs, and business records.

Morrisey thanked the local contractors who completed the construction and the Seaside Chamber of Commerce for their support during the opening.

About Seaside Storage

Seaside Storage is a locally owned and operated self-storage facility on Highway 101 in Seaside, Oregon, serving Seaside, Gearhart, Cannon Beach, Arch Cape, Warrenton, and the surrounding north Oregon coast. The facility offers heated 5×10 and 10×20 storage units with drive-up and walk-up access, electronic gated entry, and 24-hour security monitoring. Reservations are available online at SeasideStorage.com.

Media Contact
Company Name: Seaside Storage
Contact Person: Seth Morrisey
Email: Send Email
Phone: (503) 738-1118
Address:1685 N Roosevelt Dr
City: Seaside
State: OR 97138
Country: United States
Website: https://www.seasidestorage.com/

YOCTO Expands Its Services to Deliver End-to-End Retention and Lifecycle Marketing

YOCTO, a Klaviyo Elite Partner agency serving fast-growing direct-to-consumer and subscription brands, today announced an expansion of its services. The agency now offers a broader, fully integrated set of retention and lifecycle marketing capabilities designed to grow repeat revenue and customer lifetime value.

With this expansion, YOCTO now provides:

  • Klaviyo Marketing: Strategy, build-out, and ongoing management of Klaviyo programs, drawing on the agency’s Klaviyo Elite Partner status.
  • Customer Retention: Lifecycle programs built to cut churn and increase customer lifetime value.
  • Email Marketing: Lifecycle flows and campaigns that drive engagement and repeat purchases.
  • SMS Marketing: Segmented, compliant text messaging that complements email and lifecycle efforts.
  • Subscription Marketing: Programs designed to convert one-time buyers into subscribers, reduce subscription churn, and grow recurring revenue.

The expanded offering allows brands to engage YOCTO as a single retention partner across the full customer lifecycle, from acquisition follow-up through long-term subscriber retention. By bringing Klaviyo marketing, email, SMS, customer retention, and subscription programs together under one roof, the agency aims to give clients a more consistent, measurable approach to growing repeat revenue.

Media Contact
Company Name: Yocto Agency
Email: Send Email
Country: Cyprus
Website: https://yocto.agency/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: YOCTO Expands Its Services to Deliver End-to-End Retention and Lifecycle Marketing

Pavement Shield Asphalt Maintenance Becomes the Number One Choice for Asphalt Maintenance in Durham Region and the GTA

“A recently completed commercial asphalt maintenance project by Pavement Shield Asphalt Maintenance. The freshly sealed asphalt surface showcases the company’s commitment to quality workmanship, meticulous attention to detail, and professional brush-applied sealcoating services throughout Durham Region and the Greater Toronto Area.”
Pavement Shield Asphalt Maintenance continues to establish itself as a leading provider of asphalt maintenance services throughout Durham Region and the Greater Toronto Area. Specializing in brush-applied sealcoating, crack filling, line painting, asphalt repairs, and paving, the company is known for its meticulous attention to detail and commitment to quality workmanship.

DURHAM REGION, ONTARIO – When homeowners, property managers, commercial property owners, and businesses search for asphalt maintenance in Durham Region and the Greater Toronto Area, more and more are turning to Pavement Shield Asphalt Maintenance for professional workmanship, exceptional attention to detail, and long-lasting results.

Through a commitment to quality over shortcuts, Pavement Shield Asphalt Maintenance has quickly become the number one choice for asphalt maintenance, driveway sealing, parking lot maintenance, crack filling, line painting, asphalt repair, and paving services throughout Durham Region and the GTA.

What separates Pavement Shield from many competitors is its meticulous approach to every project. While many contractors rely solely on spray application methods, Pavement Shield professionally brushes its sealcoating onto the asphalt surface. This process provides superior coverage, cleaner edges, greater consistency, and a premium finish designed to protect asphalt from water penetration, UV damage, oxidation, and Ontario’s harsh freeze-thaw cycles.

“We believe details matter,” said a representative from Pavement Shield Asphalt Maintenance. “Every driveway, parking lot, and pavement surface we service receives the same level of care and attention we would expect on our own property. Our goal is simple: deliver the highest quality asphalt maintenance services available in Durham Region and the GTA.”

Complete Asphalt Maintenance Services

Pavement Shield Asphalt Maintenance provides a complete range of residential and commercial pavement services, including:

• Asphalt Sealcoating

• Driveway Sealing

• Commercial Parking Lot Sealcoating

• Asphalt Crack Filling

• Crack Sealing

• Parking Lot Line Painting

• Pavement Markings and Stenciling

• Pothole Repair

• Asphalt Patching

• Asphalt Repairs

• Catch Basin Repairs

• Asphalt Resurfacing

• Asphalt Paving

• New Asphalt Installation

• Commercial Pavement Maintenance Programs

• Property Maintenance Services

Whether protecting a residential driveway, restoring a commercial parking lot, repairing damaged pavement, or completing a large-scale paving project, Pavement Shield delivers reliable solutions that improve appearance, enhance safety, and extend pavement lifespan.

Trusted Throughout Durham Region and the Greater Toronto Area

Pavement Shield proudly serves homeowners and businesses throughout:

• Durham Region

• Pickering

• Ajax

• Whitby

• Oshawa

• Clarington

• Bowmanville

• Scarborough

• Toronto

• Markham

• Richmond Hill

• Vaughan

• North York

• Mississauga

• Brampton

• The Greater Toronto Area

As demand for professional asphalt maintenance continues to grow, Pavement Shield remains focused on providing industry-leading service, transparent communication, and exceptional workmanship on every project.

Protecting Asphalt Investments for Years to Come

Regular asphalt maintenance is one of the most cost-effective ways to protect property value and avoid expensive repairs. Through professional sealcoating, crack filling, line painting, asphalt repairs, and paving services, Pavement Shield helps clients maximize the lifespan of their pavement while maintaining a clean, professional appearance.

For property owners searching for driveway sealing in Durham Region, asphalt maintenance in the GTA, commercial parking lot line painting, crack filling services, asphalt repairs, or professional paving contractors, Pavement Shield Asphalt Maintenance continues to set the standard for quality and customer satisfaction.

About Pavement Shield Asphalt Maintenance

Pavement Shield Asphalt Maintenance is a leading asphalt maintenance company serving Durham Region and the Greater Toronto Area. The company specializes in driveway sealing, asphalt sealcoating, crack filling, parking lot line painting, asphalt repairs, pothole repairs, and paving services. Known for its brush-applied sealcoating process, meticulous attention to detail, and commitment to customer satisfaction, Pavement Shield helps homeowners and businesses protect and enhance their asphalt investments.

Contact Information

Pavement Shield Asphalt Maintenance

Phone: (289) 278-8386

Service Area: Durham Region & Greater Toronto Area

Media Contact
Company Name: Pavement Shield
Contact Person: Taylor Lantaigne
Email: Send Email
City: Whitby
State: Ontario
Country: Canada
Website: Www.Pavementshield.ca

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pavement Shield Asphalt Maintenance Becomes the Number One Choice for Asphalt Maintenance in Durham Region and the GTA

Alpha-1 Antitrypsin Deficiency Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Grifols, Kamada Pharma, Takeda, Arrowhead Pharma, Mereo BioPharma, AstraZeneca, Sanofi

The Key Alpha-1 Antitrypsin Deficiency Companies in the market include – Grifols, Kamada Pharmaceuticals, Takeda, Arrowhead Pharmaceuticals, Mereo BioPharma, AstraZeneca, Sanofi, Inhibrx Biosciences, Wave Life Sciences, Beam Therapeutics, Intellia Therapeutics, Krystal Biotech, BioMari, AlveoGene, Korro Bio, and others.

 

DelveInsight’s “Alpha-1 Antitrypsin Deficiency Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Alpha-1 Antitrypsin Deficiency, historical and forecasted epidemiology as well as the Alpha-1 Antitrypsin Deficiency market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Get a Free sample for the Alpha-1 Antitrypsin Deficiency Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-a1atd-market

 

Some of the key facts of the Alpha-1 Antitrypsin Deficiency Market Report:

  • The Alpha-1 Antitrypsin Deficiency (AATD) market size across the 7MM was valued at approximately USD 940 million in 2024 and is projected to expand significantly through 2036, driven by the increasing adoption of approved treatments and the anticipated launch of emerging therapies that are expected to enhance market penetration and broaden treatment options.

  • In May 2025, Beam Therapeutics (Nasdaq: BEAM) announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-302, a liver-targeted base editing treatment developed for alpha-1 antitrypsin deficiency (AATD) a genetic condition that leads to serious lung and liver complications and represents a significant unmet medical need.

  • In March 2025, Beam Therapeutics Inc. (Nasdaq: BEAM) announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application for BEAM-302, a potential therapy for alpha-1 antitrypsin deficiency.

  • In November 2024, Korro Bio has received approval in Australia to initiate the two-part Phase I/IIa REWRITE trial for its investigational therapy, KRRO-110, targeting alpha-1 antitrypsin deficiency (AATD). The approvals were granted by the Australian Bellberry Human Research Ethics Committee (HREC) and the Therapeutic Goods Administration (TGA).

  • The US accounts for the largest market size for AATD among the 7MM. The market size for AATD was USD 780 million in 2024.

  • According to DelveInsight’s estimates, among EU4 and the UK, Germany accounted for the largest market of in 2024, while the UK accounted for the least in the respective year.

  • In the current market, PROLASTIN/PROLASTIN-C/LYNSPAD drug accounted for the major share, which was around USD 750 million in 2024 in the 7MM.

  • As emerging treatments like gene therapies (KB408, BEAM-302, and others) and RNA-editing therapy (WAVE-006) move closer to potential approvals, the market could soon offer more durable, minimally invasive options that significantly improve patient quality of life and set new standards in Alpha-1 Antitrypsin Deficiency care.

  • Based on DelveInsight’s assessment in 2024, the 7MM had 225,950 prevalent cases of AATD. These are expected to rise due to the rising prevalence of respiratory illnesses, particularly Chronic Obstructive Pulmonary Disease (COPD) and liver diseases associated with AATD (2026−2036).

  • Among the 7MM, the US accounted for the highest number of AATD in 2024.

  • Among the EU4 and the UK, the UK accounted for the highest number of AATD cases while, Italy had the lowest cases, in 2024.

  • Japan accounted for approximately 2,950 cases of AATD in 2024.

  • Key Alpha-1 Antitrypsin Deficiency Companies: Grifols, Kamada Pharmaceuticals, Takeda, Arrowhead Pharmaceuticals, Mereo BioPharma, AstraZeneca, Sanofi, Inhibrx Biosciences, Wave Life Sciences, Beam Therapeutics, Intellia Therapeutics, Krystal Biotech, BioMari, AlveoGene, Korro Bio, and others

  • Key Alpha-1 Antitrypsin Deficiency Therapies: PROLASTIN-C LIQUID/LYNSPAD, GLASSIA, Inhaled Alpha 1-Antitrypsin (AAT), Fazirsiran (ARO-AAT/TAK-999), Inhaled AAT, Alvelestat (MPH-966), SAR447537 (INBRX-101), WVE-006, BEAM-302, NTLA-3001, KB408, BMN 349, AVG-001, KRRO-110, and others

  • The Alpha-1 Antitrypsin Deficiency market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alpha-1 Antitrypsin Deficiency pipeline products will significantly revolutionize the Alpha-1 Antitrypsin Deficiency market dynamics.

 

Alpha-1 Antitrypsin Deficiency Overview

Alpha-1 Antitrypsin Deficiency (AATD) is a genetic disorder that affects the liver and lungs. It occurs when there is a deficiency in the production of alpha-1 antitrypsin (AAT) protein, which is mainly produced by the liver and helps protect the lungs from damage caused by inflammation. Without enough AAT, the walls of the lungs can be damaged by enzymes released from white blood cells, leading to conditions such as emphysema and chronic obstructive pulmonary disease (COPD).

 

To Know in detail about the Alpha-1 Antitrypsin Deficiency market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alpha-1 Antitrypsin Deficiency Market Forecast

 

Alpha-1 Antitrypsin Deficiency Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Alpha-1 Antitrypsin Deficiency Epidemiology Segmentation:

The Alpha-1 Antitrypsin Deficiency market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Prevalent Cases of Alpha-1 Antitrypsin Deficiency

  • Total Diagnosed Prevalent Cases of Alpha-1 Antitrypsin Deficiency

  • Genotype-specific Prevalent Cases of Alpha-1 Antitrypsin Deficiency

  • Comorbidity-associated Cases of Alpha-1 Antitrypsin Deficiency

 

Download the report to understand which factors are driving Alpha-1 Antitrypsin Deficiency epidemiology trends @ Alpha-1 Antitrypsin Deficiency Epidemiology Forecast

 

Alpha-1 Antitrypsin Deficiency Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alpha-1 Antitrypsin Deficiency market or expected to get launched during the study period. The analysis covers Alpha-1 Antitrypsin Deficiency market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Alpha-1 Antitrypsin Deficiency Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Alpha-1 Antitrypsin Deficiency Therapies and Key Companies

  • PROLASTIN-C LIQUID/LYNSPAD: Grifols

  • GLASSIA: Kamada Pharmaceuticals/Takeda

  • Inhaled Alpha 1-Antitrypsin (AAT): Kamada Pharmaceuticals

  • Fazirsiran (ARO-AAT/TAK-999): Arrowhead Pharmaceuticals and Takeda

  • Inhaled AAT: Kamada Pharmaceuticals

  • Alvelestat (MPH-966): Mereo BioPharma/AstraZeneca

  • SAR447537 (INBRX-101): Sanofi/Inhibrx Biosciences

  • WVE-006: Wave Life Sciences

  • BEAM-302: Beam Therapeutics

  • NTLA-3001: Intellia Therapeutics

  • KB408: Krystal Biotech

  • BMN 349: BioMari

  • AVG-001: AlveoGene

  • KRRO-110: Korro Bio

 

Discover more about therapies set to grab major Alpha-1 Antitrypsin Deficiency market share @ Alpha-1 Antitrypsin Deficiency Treatment Landscape

 

Alpha-1 Antitrypsin Deficiency Market Drivers

  • Increasing Disease Awareness and Diagnosis: Growing awareness among healthcare professionals and improved genetic testing are leading to earlier and more accurate diagnosis of AATD.

  • Emergence of Novel Therapies: Advancements in gene therapy, RNA-based therapies, and next-generation augmentation treatments are expanding the therapeutic landscape.

  • Rising Adoption of Augmentation Therapy: Greater utilization of approved augmentation therapies for AATD-associated lung disease continues to support market growth.

  • Strong Pipeline Activity: Ongoing clinical development programs targeting the underlying genetic cause of AATD are generating significant interest from patients, clinicians, and investors.

 

Alpha-1 Antitrypsin Deficiency Market Barriers

  • Underdiagnosis and Misdiagnosis: AATD often remains undetected or is mistaken for conditions such as COPD or asthma, limiting patient identification and treatment uptake.

  • High Cost of Existing Therapies: Long-term augmentation therapy can be expensive, creating reimbursement and accessibility challenges.

  • Limited Patient Population: As a rare genetic disorder, the relatively small patient pool may constrain overall market expansion.

  • Restricted Availability of Augmentation Products: Dependence on plasma-derived therapies can create supply limitations and manufacturing challenges.

  • Lack of Curative Approved Treatments: Current therapies primarily manage symptoms and disease progression rather than addressing the root genetic defect.

 

Scope of the Alpha-1 Antitrypsin Deficiency Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Alpha-1 Antitrypsin Deficiency Companies: Grifols, Kamada Pharmaceuticals, Takeda, Arrowhead Pharmaceuticals, Mereo BioPharma, AstraZeneca, Sanofi, Inhibrx Biosciences, Wave Life Sciences, Beam Therapeutics, Intellia Therapeutics, Krystal Biotech, BioMari, AlveoGene, Korro Bio, and others

  • Key Alpha-1 Antitrypsin Deficiency Therapies: PROLASTIN-C LIQUID/LYNSPAD, GLASSIA, Inhaled Alpha 1-Antitrypsin (AAT), Fazirsiran (ARO-AAT/TAK-999), Inhaled AAT, Alvelestat (MPH-966), SAR447537 (INBRX-101), WVE-006, BEAM-302, NTLA-3001, KB408, BMN 349, AVG-001, KRRO-110, and others

  • Alpha-1 Antitrypsin Deficiency Therapeutic Assessment: Alpha-1 Antitrypsin Deficiency current marketed and Alpha-1 Antitrypsin Deficiency emerging therapies

  • Alpha-1 Antitrypsin Deficiency Market Dynamics: Alpha-1 Antitrypsin Deficiency market drivers and Alpha-1 Antitrypsin Deficiency market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Alpha-1 Antitrypsin Deficiency Unmet Needs, KOL’s views, Analyst’s views, Alpha-1 Antitrypsin Deficiency Market Access and Reimbursement

 

To know more about Alpha-1 Antitrypsin Deficiency companies working in the treatment market, visit @ Alpha-1 Antitrypsin Deficiency Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Alpha-1 Antitrypsin Deficiency Market Report Introduction

2. Executive Summary for Alpha-1 Antitrypsin Deficiency

3. SWOT analysis of Alpha-1 Antitrypsin Deficiency

4. Alpha-1 Antitrypsin Deficiency Patient Share (%) Overview at a Glance

5. Alpha-1 Antitrypsin Deficiency Market Overview at a Glance

6. Alpha-1 Antitrypsin Deficiency Disease Background and Overview

7. Alpha-1 Antitrypsin Deficiency Epidemiology and Patient Population

8. Country-Specific Patient Population of Alpha-1 Antitrypsin Deficiency

9. Alpha-1 Antitrypsin Deficiency Current Treatment and Medical Practices

10. Alpha-1 Antitrypsin Deficiency Unmet Needs

11. Alpha-1 Antitrypsin Deficiency Emerging Therapies

12. Alpha-1 Antitrypsin Deficiency Market Outlook

13. Country-Wise Alpha-1 Antitrypsin Deficiency Market Analysis (2022–2036)

14. Alpha-1 Antitrypsin Deficiency Market Access and Reimbursement of Therapies

15. Alpha-1 Antitrypsin Deficiency Market Drivers

16. Alpha-1 Antitrypsin Deficiency Market Barriers

17. Alpha-1 Antitrypsin Deficiency Appendix

18. Alpha-1 Antitrypsin Deficiency Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alpha-1 Antitrypsin Deficiency Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Grifols, Kamada Pharma, Takeda, Arrowhead Pharma, Mereo BioPharma, AstraZeneca, Sanofi

DS18 to Showcase Industry-Leading Audio Solutions at Jeep Branson, the largest Jeep event in the Midwest

Branson, MO – June 8, 2026 – DS18, a global manufacturer of high-performance mobile audio products, will attend Jeep Branson 2026 for the first time as an event sponsor, showcasing its growing lineup of Jeep-specific audio solutions.

Held in Branson, Missouri, this event helps connect Jeepers from all over the country. Its central location, compared to SE, West Coast, or Northern events, allows for fans of the iconic vehicle to attend from anywhere in the USA. The event runs for 5 energy-packed days, June 10th-14th

“We’re excited to bring Team DS18 to the Midwest. This is our first show in the region, and we’re bringing Jeeps with full DS18 systems to showcase what we’re all about,” explains Rob Ferro, Field Marketing Manager at DS18.

DS18 is attending not only as an exhibitor, but also as an event sponsor. Ferro continues “As sponsors of the event, we’ll be bringing our vendor trailer loaded with the latest products from DS18’s Jeep lineup.”

Along with the product, Rob and his team will be bringing their own Jeeps, decked out in DS18 sound systems. This will showcase both the power and reliability of DS18 technology, as well as the earnestness with which the whole DS18 family loves Jeeps and Jeepers

Ferro commented “While we definitely feel like we have products which any Jeeper would be proud to buy and install in their vehicles, we are also here because we love these Jeeps and the people who make up this community.”

The team is also very excited for attendees to have the opportunity to experience DS18’s Jeep JL sound bars, designed for plug-and-play installation and high-output performance. They are also excited to show off their newer product lines like the NVY Tower Speakers, along with the company’s new PROJECT360 loudspeakers featuring a patent-pending rotating recone design.

But as always, the core mission for the DS18 crew goes beyond showcasing their gear or selling new speakers. It’s about building community.

“We look forward to connecting with Jeep enthusiasts across the Midwest” Ferro concludes, “and welcoming more Jeepers to Team DS18.”

This is their goal for each event, but especially this upcoming week in Branson.

For more on what DS18 will present at Jeep Branson 2026, visit their Instagram (@ds18audio) or their blog, https://ds18.com/blogs/blog/.

About DS18

DS18 is a Miami-based manufacturer of professional-grade car audio and electronics, offering a wide range of speakers, amplifiers, and audio components for vehicles. With distribution in over 89 countries, DS18 is recognized for its high-output performance, bold design, and strong presence in the global car audio community.

Media Contact
Company Name: DS18
Contact Person: Patrick Edwards
Email: Send Email
Country: United States
Website: DS18.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: DS18 to Showcase Industry-Leading Audio Solutions at Jeep Branson, the largest Jeep event in the Midwest

Membranous Nephropathy Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Roche, BeOne Medicines, Biogen, Vertex Pharma, AstraZeneca, Alexion Pharma, Climb Bio

The Key Membranous Nephropathy Companies in the market include – Roche, BeOne Medicines, Biogen, Vertex Pharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Climb Bio, argenx, Tenet Medicines, Mario Negri Institute for Pharmacological, Beijing Mabworks Biotech, Shanghai Jiaolian Drug R&D, Cerium Pharmaceuticals, BeiGene, Hoffmann-La Roche, Reistone Biopharma, SynAct Pharma, Alpine Immune Sciences, Walden Biosciences, Hansa Biopharma AB, and others.

 

DelveInsight’s “Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Membranous Nephropathy, historical and forecasted epidemiology as well as the Membranous Nephropathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Get a Free sample for the Membranous Nephropathy Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/membranous-nephropathy-market

 

Some of the key facts of the Membranous Nephropathy Market Report:

  • The Membranous Nephropathy market size is anticipated to grow with a significant CAGR during the study period (2022-2036).

  • In April 2026, Climb Bio announced that the US FDA had granted Fast Track Designation (FTD) to budoprutug for the treatment of PMN.

  • In February 2026, Roche announced that the Phase III MAJESTY study in adults with primary membranous nephropathy met its primary endpoint, showing statistically significant and clinically meaningful results with obinutuzumab.

  • Roche in its Q1 2026 presentation anticipates BLA submission for obinutuzumab in membranous nephropathy in 2026.

  • Biogen in its Q1 2026 busines update anticipates felzartamab approval in 2028-2030 in primary membranous nephropathy.

  • In November 2025, povetacicept was granted FTD by the US FDA in PMN.

  • In June 2025, Biogen announced the initiation of dosing in the global clinical study, PROMINENT. The Phase III study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with PMN. Phase III data expected to read out in 2029.

  • In February 2025, Genentech, a subsidiary of Roche, has submitted positive Phase III data to the U.S. Food and Drug Administration (FDA) as it seeks to enter the lucrative lupus market with its CD20-targeting drug, Gazyva (obinutuzumab). Additionally, the company is investigating Gazyva for other autoimmune conditions, including systemic lupus erythematosus (SLE), childhood-onset idiopathic nephrotic syndrome, membranous nephropathy, and pediatric lupus nephritis.

  • IMNis often characterized by the antigens associated with the sub-epithelial immune complex deposits, some of them being PLA2R and THSD7A. Among the 7MM, PLA2R antigen accounted for maximum number of cases of IMN.

  • In 2025, IMN accounted for ~85% of total membranous nephropathy cases in the US, while secondary membranous nephropathy contributed to the remaining ~15%, highlighting the dominance of autoimmune origin in disease prevalence.

  • Across EU4 and the UK, nearly 20,000 IMN patients tested positive for the PLA2R antigen, while around 1,000 were associated with THSD7A, emphasizing the diagnostic importance of these target antigens in IMN.

  • Data from Japan indicates that the prevalence of IMN is expected to remain relatively consistent throughout the forecast period from 2026 to 2036, reflecting a stable epidemiological trend without significant increases or decreases in disease occurrence across the population during this timeframe.

  • Key Membranous Nephropathy Companies: Roche, BeOne Medicines, Biogen, Vertex Pharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Climb Bio, argenx, Tenet Medicines, Mario Negri Institute for Pharmacological, Beijing Mabworks Biotech, Shanghai Jiaolian Drug R&D, Cerium Pharmaceuticals, BeiGene, Hoffmann-La Roche, Reistone Biopharma, SynAct Pharma, Alpine Immune Sciences, Walden Biosciences, Hansa Biopharma AB, and others

  • Key Membranous Nephropathy Therapies: Obinutuzumab (GAZYVA/GAZYVARO, RG7159, GA101), Zanubrutinib (BRUKINSA), Felzartamab, Povetacicept, ALXN1920, Budoprutug, efgartigimod IV, VB119, MOR202, MIL62, B007, SNP-ACTH (1-39) Gel, Zanubrutinib, Obinutuzumab, SHR1459, AP1189, povetacicept, WAL0921, Imlifidase, and others

  • The Membranous Nephropathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Membranous Nephropathy pipeline products will significantly revolutionize the Membranous Nephropathy market dynamics.

 

Membranous Nephropathy Overview

Membranous Nephropathy is a chronic kidney disorder where the body’s immune system attacks the membranes in the glomeruli the tiny filtering units in the kidneys. This leads to thickening of the glomerular basement membrane, causing protein to leak into the urine (proteinuria). It is a common cause of nephrotic syndrome in adults. The condition can be primary (idiopathic) or secondary to other diseases like lupus, infections, cancer, or use of certain medications. Symptoms include swelling (especially in the legs), fatigue, and foamy urine. Treatment depends on the severity and underlying cause, ranging from observation to immunosuppressive therapy.

 

To Know in detail about the Membranous Nephropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Membranous Nephropathy Market Forecast

 

Membranous Nephropathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Membranous Nephropathy Epidemiology Segmentation:

The Membranous Nephropathy market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Membranous Nephropathy Prevalent Cases

  • Membranous Nephropathy Types-specific Prevalent Cases

  • Idiopathic Membranous Nephropathy (IMN) Prevalent Cases by Antigens

  • Membranous Nephropathy Treated Cases

 

Download the report to understand which factors are driving Membranous Nephropathy epidemiology trends @ Membranous Nephropathy Epidemiology Forecast

 

Membranous Nephropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Membranous Nephropathy market or expected to get launched during the study period. The analysis covers Membranous Nephropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Membranous Nephropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Membranous Nephropathy Therapies and Key Companies

  • Obinutuzumab (GAZYVA/GAZYVARO, RG7159, GA101): Roche

  • Zanubrutinib (BRUKINSA): BeOne Medicines

  • Felzartamab: Biogen

  • Povetacicept: Vertex Pharmaceuticals

  • ALXN1920: AstraZeneca / Alexion Pharmaceuticals

  • Budoprutug: Climb Bio

  • GAZYVA (obinutuzumab): Hoffmann-La Roche

  • MOR202 (felzartamab): MorphoSys/HI-Bio

  • efgartigimod IV: argenx

  • VB119: Tenet Medicines

  • MOR202: Mario Negri Institute for Pharmacological

  • MIL62: Beijing Mabworks Biotech

  • B007: Shanghai Jiaolian Drug R&D

  • SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals

  • Zanubrutinib: BeiGene

  • Obinutuzumab: Hoffmann-La Roche

  • SHR1459: Reistone Biopharma

  • AP1189: SynAct Pharma

  • povetacicept: Alpine Immune Sciences

  • WAL0921: Walden Biosciences

  • Imlifidase: Hansa Biopharma AB

 

Discover more about therapies set to grab major Membranous Nephropathy market share @ Membranous Nephropathy Treatment Landscape

 

Membranous Nephropathy Market Drivers

  • Increasing Diagnosis of Autoimmune Kidney Diseases: Improved awareness and diagnostic capabilities are leading to earlier detection of membranous nephropathy (MN), supporting market growth.

  • Advancements in Biomarker-Based Diagnosis: The use of biomarkers such as anti-PLA2R and anti-THSD7A antibodies has enhanced disease identification, monitoring, and treatment selection.

  • Emergence of Targeted Therapies: Development of novel immunomodulatory and B-cell-targeted therapies is expanding treatment options beyond conventional immunosuppressants.

  • Growing Research and Clinical Trial Activity: Increased investment in rare kidney disease research and a robust pipeline of emerging therapies are driving innovation in the MN market.

 

Membranous Nephropathy Market Barriers

  • Rare Disease Prevalence: The relatively low patient population limits market size and can reduce commercial incentives for therapy development.

  • High Cost of Advanced Therapies: Biologics and targeted treatments may impose significant financial burdens on patients and healthcare systems.

  • Complex Disease Heterogeneity: Variability in disease progression, response to treatment, and relapse rates can complicate clinical management and therapeutic development.

  • Limited Long-Term Clinical Data: Many emerging therapies still require extensive long-term efficacy and safety data before achieving widespread adoption.

 

Scope of the Membranous Nephropathy Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Membranous Nephropathy Companies: Roche, BeOne Medicines, Biogen, Vertex Pharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Climb Bio, argenx, Tenet Medicines, Mario Negri Institute for Pharmacological, Beijing Mabworks Biotech, Shanghai Jiaolian Drug R&D, Cerium Pharmaceuticals, BeiGene, Hoffmann-La Roche, Reistone Biopharma, SynAct Pharma, Alpine Immune Sciences, Walden Biosciences, Hansa Biopharma AB, and others

  • Key Membranous Nephropathy Therapies: Obinutuzumab (GAZYVA/GAZYVARO, RG7159, GA101), Zanubrutinib (BRUKINSA), Felzartamab, Povetacicept, ALXN1920, Budoprutug, efgartigimod IV, VB119, MOR202, MIL62, B007, SNP-ACTH (1-39) Gel, Zanubrutinib, Obinutuzumab, SHR1459, AP1189, povetacicept, WAL0921, Imlifidase, and others

  • Membranous Nephropathy Therapeutic Assessment: Membranous Nephropathy current marketed and Membranous Nephropathy emerging therapies

  • Membranous Nephropathy Market Dynamics: Membranous Nephropathy market drivers and Membranous Nephropathy market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Membranous Nephropathy Unmet Needs, KOL’s views, Analyst’s views, Membranous Nephropathy Market Access and Reimbursement

 

To know more about Membranous Nephropathy companies working in the treatment market, visit @ Membranous Nephropathy Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Membranous Nephropathy Market Report Introduction

2. Executive Summary for Membranous Nephropathy

3. SWOT analysis of Membranous Nephropathy

4. Membranous Nephropathy Patient Share (%) Overview at a Glance

5. Membranous Nephropathy Market Overview at a Glance

6. Membranous Nephropathy Disease Background and Overview

7. Membranous Nephropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Membranous Nephropathy

9. Membranous Nephropathy Current Treatment and Medical Practices

10. Membranous Nephropathy Unmet Needs

11. Membranous Nephropathy Emerging Therapies

12. Membranous Nephropathy Market Outlook

13. Country-Wise Membranous Nephropathy Market Analysis (2022–2036)

14. Membranous Nephropathy Market Access and Reimbursement of Therapies

15. Membranous Nephropathy Market Drivers

16. Membranous Nephropathy Market Barriers

17. Membranous Nephropathy Appendix

18. Membranous Nephropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Membranous Nephropathy Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Roche, BeOne Medicines, Biogen, Vertex Pharma, AstraZeneca, Alexion Pharma, Climb Bio

Viltrox Launches AF 75mm F1.8 EVO & AF 90mm F2.2 Lenses

Exceptionally portable lenses with versatile everyday performance, optimized for portrait photography and video

Shenzhen, China – Jun 8th, 2026 – Viltrox today announced the launch of two new APS-C portrait prime lenses: the AF 75mm F1.8 EVO and AF 90mm F2.2 EVO. Designed for APS-C mirrorless cameras, the new lenses combine professional telephoto portrait performance with compact, lightweight construction.

Versatile For Everything, Ideal for Portraits

With the introduction of the two new EVO lenses, portrait photographers can achieve strong spatial compression and smooth, atmospheric bokeh that naturally isolates subjects from distracting backgrounds. With a minimum focusing distance of just 0.74m, these lenses also enable tighter framing and immersive close-up shots for more expressive portrait compositions.

The AF 75mm F1.8 EVO offers a versatile 112.5mm-equivalent focal length that balances strong background blur with flexible everyday usability for street photography, half-body portraits, and urban shooting. The AF 90mm F2.2 EVO provides a classic 135mm-equivalent portrait perspective with enhanced compression and subject isolation, making it particularly well suited for outdoor portraits, wedding photography, and cinematic portraiture.

Improved Image Consistency Across the Frame

Viltrox has developed new optical designs incorporating ED (Extra-low Dispersion) and HR (High Refractive Index) elements to reduce chromatic aberration and contribute to improved overall image consistency. Even at maximum aperture, the lenses deliver sharp, high-resolution image quality from center to edge, while effectively helping maintain bright, consistent illumination across the frame. This results in natural tonal transitions and refined rendering characteristics.

Both lenses are equipped with Viltrox’s STM autofocus system, delivering fast, accurate, and quiet focusing performance for both photography and video. Stable, highly responsive continuous autofocus tracking helps creators maintain focus on subjects, even in dynamic shooting environments.

Both lenses also feature a customizable Fn button, an AF/MF switch, and a switchable click/de-click aperture ring** for seamless transitions between photo and video workflows.

The Everyday Carry: Compact and Lightweight Designs

The two EVO lenses continue the series’ design language with a clean exterior, compact construction, and durable build quality. Each lens weighs under 355g*, providing a lightweight alternative to traditional telephoto portrait lenses without compromising performance. With a rubber-sealed lens mount and a smudge and water-resistant coating on the front element, they are well suited to outdoor conditions.

Pricing and Availability

For more information, please visit: https://bit.ly/4dNH8zd

Amazon Store US:

AF 75mm F1.8 EVO:https://www.amazon.com/dp/B0GR419VPM

AF 90mm F2.2 EVO:https://www.amazon.com/dp/B0GR3ZQ92S

Amazon Store Europe:

AF 75mm F1.8 EVO:https://www.amazon.de/dp/B0GR419VPM

AF 90mm F2.2 EVO:https://www.amazon.de/dp/B0GR3ZQ92S

AF 75mm F1.8 EVO (E / Z / XF) – USD $329 / GBP £319 / EUR €389

AF 90mm F2.2 EVO (E / Z / XF) – USD $369 / GBP £359 / EUR €429

*Weight may vary slightly depending on the lens mount version

** XF mount version does not include the CLICK switch, Fn button, and AF/MF switch

About Viltrox

Viltrox, established in 2009, is a globally-recognized leader in camera lenses and adapters, specializing in high-performance equipment for photography and cine. The company’s portfolio includes cinema and autofocus lenses – such as the LAB, Pro, EVO, and Air series, launched since 2018 – along with monitors, adapters, and lighting solutions.

Driven by innovation, the company expanded further into cine in 2022 with the “EPIC” anamorphic and “LUNA” zoom lenses, offering cost-effective solutions for filmmakers worldwide. Renowned for their exceptional optical quality, reliability, and accessible pricing, Viltrox products reflect a commitment to engineering excellence and user-centered design, empowering content creators in both still and motion photography.

Media Contact
Company Name: Viltrox
Contact Person: Angela Liu
Email: Send Email
Country: China
Website: https://viltrox.com/

Rockefeller’s Cleaning & Restoration Co. Marks 47 Years of Disaster Restoration in New Mexico

Rockefeller’s Cleaning & Restoration Co. Marks 47 Years of Serving New Mexico in 2026 Family-Owned, Albuquerque-Based Restoration Company Celebrates Nearly Half a Century of Helping New Mexicans Recover from Fire, Flood, and Disaster — From Georgia O’Keeffe’s Home to UNM’s Zimmerman Library

ALBUQUERQUE, N.M. – Rockefeller’s Cleaning & Restoration Co., one of New Mexico’s longest-running family-owned cleaning and disaster restoration companies, is preparing to mark its 47th year in business in 2026. What began in 1979 as a side venture to fund two University of New Mexico graduate degrees has grown into a statewide operation with a30,000-square-foot facility footprint, a fleet of more than 30 vehicles, and the largest disaster restoration equipment inventory in the state.

Founded by husband-and-wife team Larry and Kelly Borgeson, Rockefeller’s was born out of necessity and built on craft. Kelly began her undergraduate studies at Carnegie-Mellon University. Larry, a U.S. Marine Corps veteran of the Vietnam War who earned the Bronze Star, a Presidential Citation, and the Purple Heart, was working for a general contractor after returning home from his service. The two came to Albuquerque together in 1975 to complete their educations at the University of New Mexico, where Larry earned BFA and MA degrees in photography and Kelly earned BFA and MA degrees in painting and drawing. The cleaning business they started together in 1979 was meant to fund their graduate school education. Forty-seven years later, it has restored some of New Mexico’s most treasured properties.

A Portfolio That Reads Like a Tour of New Mexico History

Rockefeller’s has been called in to restore Georgia O’Keeffe’s home, the University of New Mexico’s Zimmerman Library after a major flood, the El Rey Theater in downtown Albuquerque, Romano’s Macaroni Grill following a fire, and properties damaged by the Los Alamos wildfires. The company has served as the City of Albuquerque’s emergency-services board-up provider and counts among its institutional clients the University of New Mexico, Albuquerque Public Schools, Presbyterian Healthcare Services, Kirtland Air Force Base, Sandia Casino Hotel, Inn of the Mountain Gods, the National Hispanic Cultural Center, and the Sandoval and Santa Fe County courthouses.

“Our passion is revitalizing The Land of Enchantment and helping New Mexicans get back to business,” the company says on its website — a mission that has guided every restoration project for nearly five decades.

A Second Generation Carries the Torch

The Borgeson family business is now firmly in its second generation, led by the founders’ two children, Cole and Alex Borgeson. Both have worked on and off in the family businesses their entire lives, and the two are stepping into leadership together as equal partners.Cole, the elder of the two, co-launched Rockefeller’s Construction, Inc. in 2010,expanding the company into licensed general contracting and full disaster reconstruction,and is the named license-holder on New Mexico contractor license CID #366145, valid through June 2028. Alex came on in business development in 2014, bringing prior experience from Accion New Mexico and the healthcare sector. Going forward, Cole will primarily lead the construction side of the operation and Alex will primarily lead cleaning and restoration, but the two will run both companies together.

“I feel most people think that a disaster is something that might never happen to them,but as a result there tends to be a lack of preparedness,” Alex Borgeson said in an earlier profile with Albuquerque Business First — a sentiment that captures the family’s quiet, ready-when-you-need-us approach to the work.

Built for the Worst Days

Rockefeller’s operates 24 hours a day, 365 days a year, with a one-hour statewide emergency response commitment. The company is an IICRC Certified Firm and an EPA Lead-Safe Certified Firm, and its technicians hold certifications spanning water damage restoration,applied structural drying, fire and smoke restoration, applied microbial remediation, crime and trauma scene decontamination, sewage remediation, and ozone deodorization. Few competitors in New Mexico offer the company’s full breadth of specialty services, which include fine art and document restoration, oriental rug cleaning, biohazard and trauma cleanup, methamphetamine lab remediation, CS-gas and pepper-spray decontamination, hantavirus remediation, asbestos and lead abatement, and prison and holding-cell disinfection.

The company’s vertically integrated structure — cleaning, restoration, and licensed reconstruction under one roof — sets it apart from the national franchise operators that dominate much of the Albuquerque market. When a homeowner or business owner calls Rockefeller’s after a fire or flood, the same family-owned company that boards up the structure overnight will dry it out, remediate the damage, rebuild what was lost, and coordinate directly with the insurance carrier from start to finish.

Giving Back to the Land of Enchantment

Across 47 years, Rockefeller’s philanthropic footprint has grown nearly as large as itsrestoration footprint. The company has supported more than 60 New Mexico organizations,including UNM Children’s Hospital — where the Borgesons are founding members of the Circle of Dreams donor society — UNM’s Tamarind Institute, where the family funded the main entrance of the new building at Central and Stanford SE, the Albuquerque Museum, the National Hispanic Cultural Center, the Albuquerque Youth Symphony, KNME public television, Ronald McDonald House, the Salvation Army, Casa Esperanza, the Animal Humane Association, March of Dimes, the Boys & Girls Clubs of Albuquerque and Rio Rancho, ACCION New Mexico, Big Brothers Big Sisters, and dozens of local schools from Bandelier Elementary to Albuquerque High School.

For many years, Rockefeller’s donated roughly 190 Thanksgiving turkeys annually to the Salvation Army, Ronald McDonald House, the Aquinas Newman Center, and Casa Esperanza. The company has also donated thousands of dollars in HEPA air-duct cleaning services to Ronald McDonald House and Sandia Preparatory School, and contributed library books, computer software, and equipment to Albuquerque High School — along with sponsorship of the school’s Senior Lock-up graduation event, designed to keep graduating seniors safe on graduation night.

“We donate because it allows us to strengthen, even in a small way, the circle of support for each child during this critical time,” said co-founder Kelly Borgeson, in a UNM College of Fine Arts donor profile.

Looking Ahead to Year 47 and Beyond

As Rockefeller’s enters its 47th year, the company continues to invest in equipment,training, and the next generation of New Mexico restoration professionals. With the second generation now actively leading day-to-day operations and a backlog of work that spans residential homeowners recovering from summer storm flooding to institutional clients planning long-term disaster response strategies, the Borgeson family says the next chapter is about deepening the company’s roots in the state it has called home since 1975.

For homeowners, businesses, property managers, and insurance professionals across New Mexico, the message after 47 years remains the same: when disaster strikes, Rockefeller’s will be there — by your side from start to finish.

About Rockefeller’s Cleaning & Restoration Co.

Founded in 1979 in Albuquerque, New Mexico, Rockefeller’s Cleaning & Restoration Co. and its sister company Rockefeller’s Construction, Inc. are family-owned and locally operated.The company provides 24/7 statewide emergency response for fire, water, mold, storm, biohazard, and trauma damage, along with comprehensive cleaning, restoration, and reconstruction services for residential, commercial, institutional, and government clients.Rockefeller’s holds an A+ rating with the Better Business Bureau, is an IICRC Certified Firm and EPA Lead-Safe Certified Firm, and operates the largest disaster restoration equipment inventory in New Mexico.

For more information, visit www.rockefellerscleaning.com or call(505) 268-5585.

Media Contact
Company Name: Rockefeller’s Cleaning & Restoration Co.
Contact Person: Media Relations
Email: Send Email
Address:5514 Coal Ave SE
City: Albuquerque
State: NM 87108
Country: United States
Website: https://www.rockefellerscleaning.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Rockefeller’s Cleaning & Restoration Co. Marks 47 Years of Disaster Restoration in New Mexico

Woodstock Launches Woodstock MCP, a No-Code Service Connecting AI Assistants and Brokerage Accounts in Japan’s Securities Industry

Woodstock MCP enables users to connect an AI assistant to a Woodstock account and conduct activities ranging from market research to order placement through conversation, without programming.

Woodstock K.K., the company behind Woodstock, a Japanese investing app for US stocks, today launched Woodstock MCP, a service that connects an AI assistant to a brokerage account without coding. The service uses MCP, the Model Context Protocol, for this purpose without requiring programming.

Previously, linking an AI to a brokerage account for analysis or trading required building APIs and writing code, presenting a technical barrier for many investors. Woodstock MCP is designed to reduce that barrier, as setup and ongoing use do not require code.

By connecting a user’s AI assistant to their Woodstock account, the service brings market research, portfolio management, and order placement into a single conversational interface. Woodstock states that the service is intended to lower the barrier to investing through AI-assisted support.

Woodstock MCP Overview

MCP, the Model Context Protocol, is a technical standard for connecting AI assistants to external tools and data, introduced in late 2024.

Woodstock MCP builds on this standard. By linking an AI assistant to a user’s Woodstock account, it allows AI-performed analysis, drawing on external data and current news, to function as a personal investing tool. No programming knowledge is required at any stage, and users interact with their chosen AI in everyday language.

Investing Workflow Support

Woodstock MCP is designed to consolidate the investing workflow. Four stages that investors previously handled across separate tools — gathering information, analyzing it, reaching a decision, and placing an order — can be conducted within a single AI chat interface.

Woodstock MCP Features

The service supports the following functions:

  • Retrieving current figures for share prices, P/E ratios, market capitalization, and related metrics
  • Retrieving and summarizing financial statements (profit and loss, balance sheet)
  • Aggregating price changes and historical price movement for US stocks
  • Conducting analysis across market, technical, and fundamental views
  • Calculating limit order levels, such as resistance and support lines
  • Analyzing portfolio risk and preparing rebalancing proposals
  • Placing buy and sell orders in natural language, including split orders


Account Connection Process

To use Woodstock MCP, a user first applies to open an account in the Woodstock app. Once the account is open, the user connects to Woodstock MCP from their AI assistant and completes authentication.

Configuring MCP does not require code. After connection, the user interacts with the AI in everyday language. Woodstock MCP is available on desktop, mobile, and tablet.

Roadmap

Woodstock plans to develop a knowledge base of AI prompts spanning research, trading, and rebalancing. The company intends to share this material to support investment decision-making across its user base.

Availability

The Woodstock app is available for iOS and Android.

Company Overview

  • Company: Woodstock K.K.
  • Representative: Brian Yun
  • Founded: March 3, 2021
  • Website: woodstock.co
  • Financial Instruments Intermediary Service Provider: registered with the Director-General of the Kanto Local Finance Bureau, Registration No. 965
  • Affiliated Financial Instruments Business Operator: AlpacaJapan Co., Ltd.
  • AlpacaJapan registration: Financial Instruments Business Operator registered with the Director-General of the Kanto Local Finance Bureau, Registration No. 3024
  • Member associations: Japan Securities Dealers Association; Investment Management Association of Japan

Disclaimer

Before trading US stocks or other financial instruments, please read carefully the documents to be delivered prior to concluding a contract and other related materials.

When buying or selling US stocks and similar products, losses may arise as prices change in response to movements in stock markets, interest rates, and exchange rates, and to changes in the business or financial condition of issuers.

The final investment decision rests with each customer and should be made at the customer’s own judgment and responsibility.

Use of this service requires opening an account with the affiliated financial instruments business operator.

Use of Woodstock MCP requires agreement to Woodstock’s Special Provisions Concerning MCP Agent Trading.

Media Contact
Company Name: Woodstock K.K.
Contact Person: Brian Yun
Email: Send Email
Phone: +81 90 8518-1298
Address:Azabujuban, 2 Chome 20-7
State: Minato-ku, Tokyo-to
Country: Japan
Website: https://woodstock.co

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Woodstock Launches Woodstock MCP, a No-Code Service Connecting AI Assistants and Brokerage Accounts in Japan’s Securities Industry

The Boulder Group Arranges Sale of Net Leased Wendy’s Restaurant in Kalamazoo, Michigan

The Boulder Group, a net leased investment brokerage firm, completed the sale of a single tenant net leased Wendy’s restaurant located at 5455 West Main Street in Kalamazoo, Michigan for $1,600,000.

The Wendy’s property at 5455 West Main Street is situated along one of the primary retail corridors in Kalamazoo, Michigan, within Oshtemo Township. West Main Street carries approximately 29,537 vehicles per day at the intersection of Main Street and Maple Hill Drive. The property is positioned directly off the US-131 exit, providing convenient access to Interstate 94 and regional connectivity throughout southwest Michigan. The Wendy’s restaurant is surrounded by a dense concentration of national retailers and restaurants including Target, Walmart, Meijer, Kohl’s, Walgreens, Burlington, Hobby Lobby, Marshalls, PetSmart, ULTA Beauty, Five Below, Dollar Tree, Old Navy, GameStop, Dunham’s Sports, Office Depot, ALDI, Applebee’s, McDonald’s, Starbucks, Chipotle Mexican Grill, Burger King, Panera Bread, and Taco Bell. Within a 3-mile radius of the Wendy’s in Kalamazoo, the population exceeds 54,000 residents. The average household income within one mile is approximately $94,722. The median household income within three miles is approximately $55,085. The median home value within one mile is approximately $330,043. The Kalamazoo, Michigan market is home to Western Michigan University, one of the largest employers in the region. The property benefits from proximity to both US-131 and I-94, two of the most heavily traveled highways in southwest Michigan. The daytime population within three miles of the property exceeds 48,000 people, reflecting the strength of the surrounding commercial corridor.

Randy Blankstein, Jimmy Goodman and John Feeney of The Boulder Group represented the buyer in the transaction, a real estate investment group. The seller was an individual investor.

The Wendy’s at 5455 West Main Street in Kalamazoo, Michigan is leased on an absolute net basis with zero landlord responsibilities. The original lease term is 20 years with approximately 11 years remaining. The absolute net lease structure requires the tenant to pay all property taxes, insurance, and maintenance costs, providing the investor with a completely passive income stream.

The Wendy’s restaurant at 5455 West Main Street in Kalamazoo is operated by a leading restaurant company headquartered in Grand Rapids, Michigan. Meritage Hospitality Group was founded in 1986 and has grown into one of the largest Wendy’s franchise operators in the United States, managing more than 375 Wendy’s locations across 15 states. The company employs over 11,000 people and generated gross revenue of approximately $617,700,000 in 2024. The Wendy’s brand is the second-largest quick-service hamburger restaurant chain in the world, with over $12,500,000,000 in annual United States systemwide sales. The building at 5455 West Main Street was constructed in 2016 and comprises 2,600 square feet on 0.83 acres with 24 parking spaces.

“Net leased quick-service restaurant properties with long-term leases and absolute net structures continue to attract strong investor demand across all markets,” said Randy Blankstein, President of The Boulder Group. “Wendy’s remains one of the most actively traded tenants in the net lease sector due to the brand’s national recognition and proven operating performance.” Jimmy Goodman, Partner of The Boulder Group, added, “This Wendy’s property in Kalamazoo benefited from its location along a high-traffic retail corridor with over 29,500 vehicles per day and immediate proximity to the US-131 interchange, which generated significant buyer interest throughout the marketing process.” John Feeney, Senior Vice President of The Boulder Group, noted, “The buyer was attracted to the absolute net lease structure with zero landlord responsibilities and the approximately 11 years of remaining lease term, which provides a secure and passive income stream well-suited for a real estate investment fund seeking stable cash flow.”

About The Boulder Group

The Boulder Group is a boutique investment real estate service firm specializing in single tenant net lease properties. The firm provides a full range of brokerage, advisory, and financing services nationwide to a substantial and diversified client base, which includes high net worth individuals, developers, REITs, partnerships and institutional investment funds. Founded in 1997, the firm has arranged the acquisition and disposition of over $11 billion of single tenant net lease real estate transactions. From 2013–2025, the firm was ranked in the top 10 companies in the nation for single tenant retail transactions by both CoStar and MSCI Real Capital Analytics. The Boulder Group is headquartered in suburban Chicago and has an office in Denver.

More info: www.bouldergroup.com

Media Contact
Company Name: The Boulder Group
Contact Person: Randy Blankstein
Email: Send Email
Phone: 8478816388
Address:3520 Lake Avenue Suite 203
City: Wilmette
State: Illinois
Country: United States
Website: https://www.bouldergroup.com/NNN-Properties-For-Sale.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Boulder Group Arranges Sale of Net Leased Wendy’s Restaurant in Kalamazoo, Michigan